FDA 执法报告 D-0052-2027 显示 Pfizer 的 Levoxyl 175 mcg 因稳定性试验确认 OOS 含量不合格被列为 II 类召回
FDA drug enforcement D-0052-2027: Pfizer — Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
FDA 药品执法报告 D-0052-2027 将 Pfizer 的 Levoxyl(左甲状腺素钠片,USP)175 mcg 片剂列为 II 类召回,原因为稳定性试验中确认含量不符合标准(OOS)导致效价不足。
记录列出稳定性试验确认含量不合格导致的效价不足召回,含批次、分销范围与状态,可用于核对召回档案。
FDA drug recall enforcement report — D-0052-2027
Report issued: 2026-10-28. This is the enforcement report date, not the recall initiation date.
Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.
The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.
Complete official product record (including openFDA harmonized identifiers):
{
"address_1": "66 Hudson Blvd",
"address_2": "",
"center_classification_date": "20261016",
"city": "Manhattan",
"classification": "Class II",
"code_info": "Lot # 24W06, Exp: 11/30/2026",
"country": "United States",
"distribution_pattern": "US Nationwide and Puerto Rico",
"event_id": "99963",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"NDA021301"
],
"brand_name": [
"LEVOXYL"
],
"generic_name": [
"LEVOTHYROXINE SODIUM"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Pfizer Laboratories Div Pfizer Inc"
],
"package_ndc": [
"60793-850-10",
"60793-850-01",
"60793-851-10",
"60793-851-01",
"60793-852-10",
"60793-852-01",
"60793-853-10",
"60793-853-01",
"60793-854-10",
"60793-854-01",
"60793-855-10",
"60793-855-01",
"60793-856-10",
"60793-856-01",
"60793-857-10",
"60793-857-01",
"60793-858-10",
"60793-858-01",
"60793-859-10",
"60793-859-01",
"60793-860-10",
"60793-860-01"
],
"product_ndc": [
"60793-850",
"60793-851",
"60793-852",
"60793-853",
"60793-854",
"60793-855",
"60793-856",
"60793-857",
"60793-858",
"60793-859",
"60793-860"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"892246",
"892251",
"966157",
"966164",
"966170",
"966175",
"966184",
"966190",
"966194",
"966200",
"966204",
"966211",
"966220",
"966221",
"966222",
"966224",
"966225",
"966248",
"966249",
"966253",
"966270",
"966283"
],
"spl_id": [
"8ce3c272-807b-4a86-aa58-034013814264"
],
"spl_set_id": [
"758588c3-c63e-491b-0aa2-4f50d80cb174"
],
"substance_name": [
"LEVOTHYROXINE SODIUM"
],
"unii": [
"9J765S329G"
],
"upc": [
"0360793858012",
"0360793855011",
"0360793852010",
"0360793860015",
"0360793850016",
"0360793853017",
"0360793854014",
"0360793857015",
"0360793859019",
"0360793856018",
"0360793851013"
]
},
"postal_code": "10001-2189",
"product_description": "Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.",
"product_quantity": "15,815 100-count bottles",
"product_type": "Drugs",
"reason_for_recall": "Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.",
"recall_initiation_date": "20260929",
"recall_number": "D-0052-2027",
"recalling_firm": "Pfizer",
"report_date": "20261028",
"state": "NY",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov